… Aspirin is recommended by clinical practice guidelines for preventing ischemic events among
patients at high risk for or with established cardiovascular disease (ie, history of peripheral …

… We found 15 studies which together included more than 30,000 people at high risk of heart
disease who are taking aspirin. All studies randomly assigned participants to the intervention …

… baseline risk factors among the different dose cohorts were clearly imbalanced, it is possible
that physicians in our study selected higher doses of aspirin for patients at greater risk, …

… Dual therapy was associated with significantly increased risk for major bleeding in … aspirin
and clopidogrel significantly reduces the odds of major cardiovascular events in patients with …

… patients with either clinically evident cardiovascular disease or multiple risk factors to receive
clopidogrel (75 mg per day) plus … in patients at high risk for a cardiovascular event. The …

… and safety of clopidogrel plus aspirin versus placebo plus aspirin in patients with established
… To fulfill the coronary artery disease criteria, patients must have one of the following …

… We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit
than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. …

… of vascular disease or other vascular-related diseases, in … adding aspirin to clopidogrel
therapy significantly increased … in the prevention of major cardiovascular events, myocardial …

… aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease
relative to the increased risk … ) tested clopidogrel plus aspirin versus aspirin alone in patients …

… or higher risk than those enrolled in CHARISMA. In particular, extending our findings to
patients at lower or higher risk of CV events than those studied in CHARISMA would require both …